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Background: The effect of BEV to neo-adjuvant chemotherapy is modest in unselected
HER2-negative (HER2-) breast cancer (BC) patients. VEGF-A has been suggested as a
predictor for response to neoadjuvant BEV. We estimated the cost-effectiveness of
using VEGF-A testing and corresponding treatment strategies in the neoadjuvant
treatment of hormone receptor (estrogen or progesterone) positive (HR+), HER2- BC.
Methods: Using a life-long Markov state transition model, we determined the health
economic impact and incremental cost-effectiveness ration (ICER) of VEGF-A guided
use of BEV therapy. Six alternative strategies were compared (four different VEGF-A
cut-off values; two implying the use of BEV in no or all patients. Overall and
metastasis-free survival information was derived from GeparQuinto (n = 830) trial
(EudraCT No: 2006-005834-19). Effectiveness was assessed as quality-adjusted
life-years (QALYs). Costs (in EUR, year 2013) were assessed from a German
third-party payer perspective.
Results: Lifetime costs per patient ranged from EUR 37’042 (reference strategy; no
BEV) to EUR 78’367 (BEV to all). No BEV therapy yielded 14.031 QALYs per patient.
The VEGF-A guided strategies achieved between 14.220 (cut-off 450 pg/mL) and
14.235 (cut-off 339 pg/mL) QALYs. In comparison with no BEV therapy, the most
preferable strategy (cut-off 450 pg/mL) yielded additional costs of 11’191 EUR and
0.189 QALYs per patient (ICER 59’161 EUR/QALY) (Tab 1, only undominated
strategies shown). Results remained robust in deterministic sensitivity analyses.
Conclusion: Our study suggests that VEGF-A testing could be sensibly used to
guide the neo-adjuvant administration of BEV in HR+ HER2- BC. Compared to not
using BEV, the use of a cut-off value of 450 pg/mL might be cost-effective in
Germany. Tab 1
Table: 45P
Cost
(EUR)
Incremental
Cost (EUR)
QALY Incremental
effect (QALY)
ICER (EUR/QALY)
No test, no BEV 37’042 14,031
VEGF-A 450 48’233 11’191 14,220 0,189 59’161
(vs. reference)
VEGF-A 400 50380 1’338 14,230 0,199 227’344
(vs. VEGF-A 450)
VEGF-A 339 54’061 17’019 14,235 0,204 673’769
(vs. VEGF-A 400)
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